Patient‐centred and professional‐directed implementation strategies for diabetes guidelines: a cluster‐randomized trial‐based cost‐effectiveness analysis

Aims  Economic evaluations of diabetes interventions do not usually include analyses on effects and cost of implementation strategies. This leads to optimistic cost‐effectiveness estimates. This study reports empirical findings on the cost‐effectiveness of two implementation strategies compared with usual hospital outpatient care. It includes both patient‐related and intervention‐related cost.

[1]  G. Rutten,et al.  NHG-standaard Diabetes Mellitus type 2 (eerste herziening) , 1999 .

[2]  J M Grimshaw,et al.  Effectiveness and efficiency of guideline dissemination and implementation strategies , 2004, International Journal of Technology Assessment in Health Care.

[3]  L. Niessen,et al.  Cost-effectiveness of glycemic control and ophthalmological care in diabetic retinopathy. , 2003, Health policy.

[4]  T. Sano,et al.  [Diabetic retinopathy]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[5]  E. Standl,et al.  Microalbuminuria in a random cohort of recently diagnosed type 2 (non-insulin-dependent) diabetic patients living in the Greater Munich Area , 1993, Diabetologia.

[6]  Paul Fenn,et al.  Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) , 2000, BMJ : British Medical Journal.

[7]  P. Bingley,et al.  Islet autoantibodies, nationality and gender: a multinational screening study in first-degree relatives of patients with Type I diabetes , 2002, Diabetologia.

[8]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[9]  D. Klonoff,et al.  An economic analysis of interventions for diabetes. , 2000, Diabetes care.

[10]  R. Dijkstra,et al.  Patients and nurses determine variation in adherence to guidelines at Dutch hospitals more than internists or settings , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[11]  P. Zimmet,et al.  The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010 , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[12]  R. Glasgow,et al.  In diabetes care, moving from compliance to adherence is not enough. Something entirely different is needed. , 1999, Diabetes care.

[13]  L. Niessen.  Roads To Health: Multi-State Modelling Of Population Health And Resource Use , 2003 .

[14]  Harlan M Krumholz,et al.  Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. , 2002, Journal of the American College of Cardiology.

[15]  J. Rakela,et al.  Gedetailleerde raming van de maatschappelijke kosten van diabetes mellitus , 2000 .

[16]  L. Niessen,et al.  Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis. , 2004, Diabetes care.

[17]  R. Hutubessy,et al.  Stochastic league tables: an application to diabetes interventions in the Netherlands. , 2005, Health economics.

[18]  J. Bommer,et al.  Prevalence and socio-economic aspects of chronic kidney disease. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  Jan B Oostenbrink,et al.  Standardisation of costs: the Dutch Manual for Costing in economic evaluations. , 2002, PharmacoEconomics.

[20]  H. Bilo,et al.  Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines. , 2000, Health policy.

[21]  R. Ratner.  Type 2 diabetes mellitus: the grand overview , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[22]  M. Koopmanschap,et al.  Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. , 2002, Diabetes care.

[23]  P. M. Brown,et al.  Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[24]  E. Ritz,et al.  Renal disease and hypertension in non-insulin-dependent diabetes mellitus. , 1999, Kidney international.

[25]  R. Hutubessy,et al.  Lifetime health effects and costs of diabetes treatment. , 2003, The Netherlands journal of medicine.

[26]  F. Rutten,et al.  The evidence-based approach in health policy and health care delivery. , 2000, Social science & medicine.

[27]  Frode Gallefoss,et al.  Cost-benefit and cost-effectiveness analysis of self-management in patients with COPD--a 1-year follow-up randomized, controlled trial. , 2002, Respiratory medicine.

[28]  R. Grol,et al.  Empowering patients: how to implement a diabetes passport in hospital care. , 2002, Patient education and counseling.

[29]  N Freemantle,et al.  When is it cost-effective to change the behavior of health professionals? , 2001, JAMA.

[30]  R. Grol,et al.  Perceived barriers to the implementation of diabetes guidelines in hospitals in The Netherlands. , 2000, The Netherlands journal of medicine.

[31]  L. Gaal,et al.  Assessing the impact of complications on the costs of Type II diabetes , 2002, Diabetologia.

[32]  R. Grol,et al.  Introduction of diabetes passports involving both patients and professionals to improve hospital outpatient diabetes care. , 2005, Diabetes research and clinical practice.

[33]  A. Zbrozek,et al.  Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia , 1997, Diabetes Care.